BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) saw its price target raised to $60 from $55 by H.C. Wainwright on December 22. The firm noted that the acquisition of Amicus Therapeutics Inc. (NASDAQ:FOLD) stabilizes cash flows, but peak sales may not happen until the 2030s, with Voxzogo driving stock value in the interim.

On December 19, BioMarin announced a $4.8 billion all-cash acquisition of Amicus Therapeutics, valued at $14.50 per share. The merger, approved by both Boards of Directors, is set to close in Q2 2026 pending regulatory clearances and Amicus stockholder approval.

BioMarin’s acquisition of Amicus adds two therapies for lysosomal storage disorders and US rights to a Phase 3 investigational drug for a rare kidney disease. The acquired products generated $599 million in revenue over the last four quarters.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for rare diseases worldwide. The company focuses on life-threatening conditions in various regions including the US, Europe, Latin America, and the Asia Pacific.

While BioMarin (BMRN) shows investment potential, certain AI stocks may offer greater upside with less downside risk. For those seeking an undervalued AI stock benefiting from Trump-era tariffs and onshoring trends, consider the best short-term AI stock.

Read more at Yahoo Finance: BioMarin’s (BMRN) Amicus Acquisition Stabilizes Cash Flow While Voxzogo Remains Near-Term Driver